DeepTag-GPRC5D
Phase 1- Indications
- Relapsed/refractory multiple myeloma
Company intelligence / Profile preview
DeepTag Therapeutics
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
DeepTag is conducting clinical trials for DeepTag-GPRC5D CAR-T cell therapy in 60 patients with relapsed refractory multiple myeloma[6]
- Therapeutic areas
- Oncology
- Modalities
- Protein-protein interactionssmall moleculespeptidesCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cytel Inc.
Beyond the preview
Go deeper on DeepTag Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DeepTag Therapeutics.